All In Biotech

Drug Trial Radar · NCT02499835

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer

Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Aug 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

66

Actual

Start

Jul 1, 2015

Primary completion

Aug 9, 2021

Study completion Jul 27, 2023

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Prostate Cancer Foundation; Madison Vaccines Incorporated
First posted
Jul 16, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized pilot trial studies vaccine therapy and pembrolizumab in treating patients with prostate cancer that does not respond to treatment with hormones (hormone-resistant) and has spread to other places in the body (metastatic). Vaccines made from deoxyribonucleic acid (DNA), such as pTVG-HP plasmid DNA vaccine, may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as pembrolizumab, may find tumor cells and help kill them. Giving pTVG-HP plasmid DNA vaccine and pembrolizumab may kill more tumor cells.

Conditions

  • Hormone-Resistant Prostate Cancer
  • Metastatic Malignant Neoplasm in the Bone
  • Metastatic Malignant Neoplasm in the Soft Tissues
  • Metastatic Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Recurrent Prostate Carcinoma
  • Stage IV Prostate Cancer

Interventions

  • PembrolizumabBiological

    Given IV

  • pTVG-HP Plasmid DNA VaccineBiological

    Given ID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events, Using the National Cancer Common Terminology Criteria, Version 4Time frame: Up to 23 months (Up to 12 months after completion of study treatment)
  2. 6-month Progression Free Survival RateTime frame: 6 months
  3. Median Time to Radiographic ProgressionTime frame: Up to 2 years
  4. Number of Participants Who Have an Objective ResponseTime frame: Up to 2 years
  5. Number of Participants Who Have a PSA ResponseTime frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.